After 12 weeks of treatment, a greater proportion of patients had better control of the signs and symptoms of RA (ACR50 and ACR70) and reduction of disease activity (DAS28-CRP < 2.6, SDAI ≤ 3.3, and CDAI ≤ 2.8) with sarilumab 200 mg + MTX compared with sarilumab 150 mg + MTX. The gene discussed is CRP; the disease is rheumatoid arthritis.